ストックスクリーナーアプリを入手
8.78
2.66%
-0.25
前日終値:
$9.03
開ける：
$9
24時間の取引高:
111.78K
Relative Volume:
0.32
時価総額：
$287.97M
収益：
$65.42M
当期純損益:
$-32.96M
株価収益率:
-6.9134
EPS:
-1.27
ネットキャッシュフロー:
$-19.87M
1週間 パフォーマンス:
-2.12%
1か月 パフォーマンス:
-5.99%
6か月 パフォーマンス:
-28.59%
1年 パフォーマンス:
+23.89%
1日の値動き範囲:
$8.71
$9.22
1週間の範囲:
$7.5625
$9.6788
52週間の値動き範囲:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
NPCE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
8.78 | 305.68M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
131.67 | 225.22B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.12 | 151.88B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
382.28 | 144.88B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.00 | 119.04B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.31 | 45.61B | 5.69B | 1.41B | 577.90M | 6.95 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
Wells Fargo & Company Has Lowered Expectations for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results - MarketBeat
Neuropace’s Innovative Approach to Treating Lennox-Gastaut Syndrome - TipRanks
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
NeuroPace stock price target lowered to $13 by Wolfe Research - Investing.com South Africa
AI Trend Models Suggest Bounce for NeuroPace Inc.Weekly Trading Summary & Daily Entry Point Trade Alerts - kangso.co.kr
NeuroPace Raises 2025 Revenue Guidance to $94-98 Million on Strong RNS System Sales. - AInvest
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15 - 富途牛牛
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
NeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call Transcript - Insider Monkey
NeuroPace Q2 Loss Wider Than Expected, Revenue Exceeds ForecastsNews and Statistics - IndexBox
NeuroPace 2025 Q2 Earnings Revenue Growth Amid Sustained Net Loss - AInvest
NeuroPace stock price target lowered to $15 by Wells Fargo on wider loss forecast - Investing.com South Africa
NeuroPace Inc.: Q2 Earnings Snapshot - Greenwich Time
NeuroPace Expects FDA Submission for Expanded IGE Indication in 2H 2025 - AInvest
NeuroPace Q2 Revenue Hits $23.5M, Up 22% YoY, With Gross Margin at 77.1% - AInvest
NeuroPace Inc (NPCE) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... By GuruFocus - Investing.com Canada
NeuroPace Reports Record Revenue and Raises Guidance - TipRanks
Is NeuroPace Inc. in Accumulation Phase NowAI Based High Gain Watchlist Scanner Shared - beatles.ru
NeuroPace Q2 2025 Earnings Call Transcript - MarketBeat
NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth - MSN
NeuroPace: Building a Durable Moat in Epilepsy Treatment with AI-Driven Innovation and Expanding Indications - AInvest
NeuroPace Revenue Jumps 22 Percent in Q2 - Nasdaq
NeuroPace Raises 2025 Revenue Guidance to $94M-$98M, Driven by RNS System Growth - AInvest
NeuroPace's Q2 2025 Earnings Call: Unraveling Key Contradictions in Growth, Margins, and Strategy - AInvest
NeuroPace, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NPCE) - Seeking Alpha
Transcript : NeuroPace, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
NeuroPace's (NPCE) Q2 Performance: A Miss on Earnings, but a Win for the Future? - AInvest
NeuroPace (NPCE) Q2 2025 Earnings Call Transcript - AOL.com
NeuroPace Achieves Record Q2 Revenue, Raises Full-Year Outlook to $94-$98 Million - AInvest
NeuroPace Outpaces Expectations Thanks To RNS System Sales - Finimize
Earnings call transcript: Neuropace Q2 2025 sees revenue rise; stock gains 2.7% - Investing.com Canada
NeuroPace Reports Record Q2 Revenue - AOL.com
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
NeuroPace Inc SEC 10-Q Report - TradingView
Neuropace Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neuropace earnings missed by $0.04, revenue topped estimates - Investing.com Canada
NeuroPace's Q2 2025 Earnings: A Tale of Two Metrics and the Road to Long-Term Growth - AInvest
NeuroPace Reports Record Q2 2025 Revenue of $23.5 Million, Increases 2025 Guidance - AInvest
NeuroPace Q2 revenue $23.5mln, up 22% YoY, raises FY25 guidance to $94-$98mln. - AInvest
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - GlobeNewswire
Can NeuroPace Inc. sustain earnings growthBottom Fishing Opportunity - newsyoung.net
NeuroPace Receives Buy Rating from Lake Street Analyst - AInvest
Is NeuroPace Inc. the Top Chart Pick This WeekTrend Analysis for Safer Trades Gains Popularity - sundaytimes.kr
What risks could impact NeuroPace Inc. stock performanceShort Term Momentum Based Trading Strategy - Newser
Applying chart zones and confluence areas to NeuroPace Inc.Free Community Verified Stock Suggestions - Newser
What the charts say about NeuroPace Inc. todayWatchlist Summary for Active Day Traders - Newser
Will NeuroPace Inc. bounce back from current supportHigh Win Rate Strategy with Stop Protection - Newser
Technical signs of recovery in NeuroPace Inc.Daily Market Movers Screener with Filters - Newser
Is a relief rally coming for NeuroPace Inc. holdersFree Triple Return Setup with Risk Control - Newser
News impact scoring models applied to NeuroPace Inc.Swing Trade Timing with Daily Forecast - Newser
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
Neuropace Inc (NPCE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.70%
0.37%
大文字化:
|
ボリューム (24 時間):